plus therapeutics - Robuta Search

https://www.biospace.com/press-releases/plus-therapeutics-announces-initial-patients-successfully-treated-in-respect-lm-dose-optimization-trial-for-reyobiq-in-leptomeningeal-metastases Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization... plus therapeutics https://www.biospace.com/plus-therapeutics-announces-share-repurchase-program-october-31-2023 Plus Therapeutics Announces Share Repurchase Program - October 31, 2023 - BioSpace Nov 1, 2023 - Plus Therapeutics, Inc. announced that its Board of Directors has approved a share repurchase program, with authorization to repurchase up to $500,000 of the... share repurchase program plus therapeutics october 31 announces 2023 https://www.biospace.com/press-releases/plus-therapeutics-announces-leadership-appointments-for-its-cnside-diagnostics-subsidiary Plus Therapeutics Announces Leadership Appointments for its CNSide Diagnostics Subsidiary - BioSpace plus therapeutics announces leadership appointments https://www.macrotrends.net/stocks/charts/PSTV/plus-therapeutics/cash-on-hand Plus Therapeutics Cash on Hand 2012-2025 | PSTV | MacroTrends Plus Therapeutics cash on hand from 2012 to 2025. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at... cash on hand plus therapeutics 2012 2025 pstv https://www.biospace.com/plus-therapeutics-announces-dr-gregory-stein-as-head-of-clinical-development Plus Therapeutics Announces Dr. Gregory Stein as Head of Clinical Development - BioSpace Apr 2, 2020 - Plus Therapeutics, Inc., announced that Dr. Gregory Stein has joined the Company as Senior Vice President of Clinical Development. plus therapeutics https://www.biospace.com/plus-therapeutics-receives-4-6mm-reimbursement-payment Plus Therapeutics Receives $4.6MM Reimbursement Payment - BioSpace Oct 15, 2019 - Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development, and manufacturing scale up of complex and innovative... plus therapeutics 4 6mm receives reimbursement payment https://www.globenewswire.com/news-release/2025/03/04/3036891/0/en/Plus-Therapeutics-Secures-Private-Placement-of-Approximately-15-Million-in-Gross-Proceeds.html Plus Therapeutics Secures Private Placement of Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds ... plus therapeutics private placement secures https://www.biospace.com/press-releases/plus-therapeutics-reports-first-quarter-financial-results-and-recent-business-highlights Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights - BioSpace plus therapeutics first quarter financial results https://www.globenewswire.com/news-release/2025/05/23/3087728/0/en/Plus-Therapeutics-Inc-Receives-Notification-of-Deficiency-from-Nasdaq-Related-to-Delayed-Filing-of-Quarterly-Report-on-Form-10-Q.html Plus Therapeutics, Inc. Receives Notification of Deficiency Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q... plus therapeutics inc receives notification deficiency https://www.home.saxo/de-ch/markets/stocks/pstv-xnas Plus Therapeutics Inc. aktie | Saxo Bank Schweiz Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, commercializing and delivering complex treatments for... plus therapeutics saxo bank inc aktie schweiz https://www.biospace.com/press-releases/tango-therapeutics-announces-first-patient-dosed-in-phase-1-2-trial-of-tng462-plus-revolution-medicines-daraxonrasib-or-zoldonrasib-in-patients-with-ras-mutant-mtap-deleted-pancreatic-or-lung-cancer Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution... https://www.biospace.com/press-releases/plus-therapeutics-to-announce-fourth-quarter-and-full-year-2024-financial-results-and-host-conference-call-on-march-27-2025 Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host... https://www.fiercebiotech.com/medtech/roivant-sciences-to-absorb-silicon-therapeutics-into-its-vantai-outfit-450m-deal Roivant Sciences to absorb Silicon Therapeutics with $450M-plus deal | Fierce Biotech Feb 26, 2021 - Roivant Sciences has moved to take molecule designer Silicon Therapeutics underneath its corporate umbrella in a deal worth $450 million or more that wi roivant sciences